Syngene International Ltd
Syngene International Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Get Syngene International Ltd's next results in your feed
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Syngene expects continued revenue growth driven by strong momentum in Research Services, accounting for 67% of sales in Q1 FY '26. Syngene expects underlying revenue growth in early teens for FY '26 after adjusting for client inventory rebalancing in biologics commercial manufacturing.
From Syngene International Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Syngene expects continued revenue growth driven by strong momentum in Research Services, accounting for 67% of sales in Q1 FY '26.
- Early signs point to healthy pipeline development and conversion of pilot projects into full contracts.
- The biologics business, including new Unit 3 and Bayview facilities, is expected to ramp up over 3 to 5 years, with efforts to accelerate this timeline where possible.
- Underlying business growth is expected in the early teens annually, but overall reported revenue growth is guided in mid-single digits due to client inventory adjustments in biologics manufacturing.
- Capacity utilization in small molecule manufacturing (Mangalore) is expected to increase over the year.
2 more points from Syngene International Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Syngene incurred around $8 million capex during the quarter across businesses.
- Approximately 30% of capex invested in Research Services focusing on capability builds, including peptides, ADCs, and dedicated centres.
- Nearly 55% of capex directed towards CDMO business for new formulation facilities in small molecules and modifications at Unit 3 biologics facility.
- Remaining capex spent on digitization, automation, and common infrastructure.
- Plans to continue strategic investments and capability builds to be future-ready.
- Unit 3 and Bayview biologics facilities are becoming operational in FY '26, with ramp-up expected over 3 to 5 years.
2 more points from Syngene International Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- There is mention of a healthy pipeline of pilot projects in the Research Services business, including strong interest and ongoing conversion of pilot CRO projects into full-fledged contracts.
- Bayview facility in the US is seeing healthy interest from potential customers.
- The complex nature of client project structures (with some like Emergent having potential rights of first refusal) indicates ongoing client engagements but without disclosing specific order volumes.
- Overall, the company expresses optimism about pipeline growth and business conversion but refrains from sharing concrete order book numbers currently.
Syngene International Ltd — Quarterly revenue & net profit
Syngene International Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 874 | 790 | +10.6% | 1,018 | -14.1% |
| Operating profit (EBITDA) | 206 | 170 | +21.2% | 344 | -40.1% |
| Operating margin | 24% | 22% | +2 pp | 34% | -10 pp |
| Profit before tax | 101 | 101 | 0% | 240 | -57.9% |
| Net profit (PAT) | 87 | 76 | +14.5% | 183 | -52.5% |
| EPS (₹) | 2.15 | 1.88 | +14.4% | 4.55 | -52.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹833 Cr, net profit ₹32 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Syngene International's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Aster DM Quality Care Ltd (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
- Yatharth Hospital & Trauma Care Services (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
- Rainbow Childrens Medicare (Q1 FY26)
Around 50% of the total planned bed additions will be on an asset-light model. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1 FY26 earnings…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Syngene International Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Syngene International Ltd Q1 FY26 results?
Syngene expects continued revenue growth driven by strong momentum in Research Services, accounting for 67% of sales in Q1 FY '26. Syngene expects underlying revenue growth in early teens for FY '26 after adjusting for client inventory rebalancing in biologics commercial manufacturing.
What is Syngene International Ltd share price analysis?
Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 55.5 with a market cap of ₹16,427 Cr. Investors should review the full earnings analysis for detailed insights.
Is Syngene International Ltd planning capital expenditure?
Syngene incurred around $8 million capex during the quarter across businesses.
Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.